Tendering and biosimilars: what role for value-added services?

References

• Leopold C, Habl C, Vogler S. Tendering of pharmaceuticals in EU member states and EEA countries. Results from the country survey. 2008. [cited 2019 Feb 20]. Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Final_Report_Tendering_June_08_7.pdf
   Google Scholar
• Dranitsaris G, Jacobs I, Kirchhoff C, et al. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res. 2017;9:573–8.
   PubMed Web of Science ®Google Scholar
• HighPoint Solutions. An IQVIA company. Tendering in the procurement environment. 2016. [cited 2019 May 9]. Available from: http://blog.highpointsolutions.com/tendering-in-the-procurement-environment
   Google Scholar
• Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy. 2011;101(2):146–152.
   PubMed Web of Science ®Google Scholar
• Wenzel M, Henne N, Zollner Y. Beyond the pill: the move towards value-added services in the pharmaceutical industry. J Med Mark. 2014;14(2–3):91–98.
   Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP Jr., et al. Defining elements of value in health care-A health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Kober S. The value of value-added services. Biotechnol Health. 2008;5(3):43–44.
   Google Scholar
• HighPoint Solutions. An IQVIA company. Tender management practices in the life sciences industry, report 2. 2017. [cited 2019 May 9]. Available from: https://cdn2.hubspot.net/hubfs/1801932/Collateral/Tender-Management-Benchmarking-Survey-R2.pdf
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products. 2014. [cited 2019 Feb 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
   Google Scholar
• US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. [cited 2019 May 16]. Available from: https://www.fda.gov/media/82647/download
   Google Scholar
• World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. [cited 2019 Feb 20]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
   Google Scholar
• Simoens S, Jacobs I, Popovian R, et al. Assessing the value of biosimilars: a review of the role of budget impact analysis. Pharmacoeconomics. 2017;35(10):1047–1062.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European public assessment reports. Biosimilars. [cited 2019 Feb 20]. Available from: https://www.ema.europa.eu/en/medicines
   Google Scholar
• Mauskopf J, Hogue S, Miller D. Competitive bidding for therapeutically equivalent branded drugs. 2015. [cited 2019 Feb 20]. Available from: http://concilioconsulting.com/litreview/Therapeutic%20tendering%20presentation.pdf
   Google Scholar
• IMS. Institute for Healthcare Informatics. Delivering on the Potential of Biosimilar Medicines. The Role of Functioning Competitive Markets. 2016. [cited 2019 Feb 20]. Available from: http://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf
   Google Scholar
• Vogler S, Gombocz M, Zimmermann N. Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. J Pharm Health Serv Res. 2017;8:147–158.
   Google Scholar
• Cantini F, Benucci M. Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? Ann Rheum Dis. 2019;78(4):e23.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–1431.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sorensen J, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open. 2018;4(2):e000710.
   PubMed Web of Science ®Google Scholar
• European Parliament Council of the European Union. Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and repealing Directive 2004/18/EC Text with EEA relevance. 2014. [cited 2019 Jan 29]. Available from: https://eur-lex.europa.eu/eli/dir/2014/24/oj/eng
   Google Scholar
• Martens M, Carbonnelle N. White paper. Public procurement of medicinal products. Common legislation but diverging implementation approaches throughout the EU. 2014. [cited 2018 Oct 31]. Available from: https://www.twobirds.com/~/media/pdfs/white-papers/public-procurement-of-medicinal-products.pdf
   Google Scholar
• EuropaBIO. White paper on public procurement of biological medicines. 2015. [cited 2018 Dec 14]. Available from: http://www.europabio.org/sites/default/files/europabio_white_paper_on_public_procurement_of_biological_medicines_final.pdf
   Google Scholar
• Reiland J-B, Freischem B, Roediger A. What pricing and reimbursement policies to use for off-patent biologicals in Europe? – results from the second EBE biological medicines policy survey. GaBI J. 2017;6(2):61–78.
   Google Scholar
• Medicines for Europe. Market review – biosimilar medicines markets. Policy overview. 2017. [cited 2018 Dec 14]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2017/09/Market-Review-biosimilar-medicines-market-2017.pdf
   Google Scholar
• Remuzat C, Kapusniak A, Caban A, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017;5(1):1307315.
   PubMedGoogle Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12):e0190147.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in central and Eastern European countries. Front Pharmacol. 2017;8:288.
   PubMed Web of Science ®Google Scholar
• Medicines for Europe. Fulfilling the biosimilar promise: report highlights key principles in support of a sustainable market. 2016. [cited 2018 Dec 14]. Available from: http://www.medicinesforeurope.com/news/fulfilling-the-biosimilar-promise-report-highlights-key-principles-in-support-of-a-sustainable-market/
   Google Scholar
• GfK Market Access. Factors supporting a sustainable european biosimilar medicines market. final project report. 2014. [cited 2018 Dec 14]. Available from: http://www.medicinesforeurope.com/wp-content/uploads/2016/03/GfK_Final_Report-_Factors_Supporting_a_Sustainable_European_Biosimilar_Medicines_Market.pdf
   Google Scholar
• European Federation of Pharmaceutical Industries and Associations. EFPIA policy principles for off-patent biologic medicines in Europe. 2015. [cited 2018 Dec 14]. Available from: https://www.efpia.eu/media/25877/efpia-principles-for-off-patent-biologic-medicines-in-europe-30092015.pdf
   Google Scholar
• IQVIA. Institute for human data science. advancing biosimilar sustainability in Europe: a multi-stakeholder assessment. 2018. [cited 2019 Jan 29]. Available from: https://www.iqvia.com/en/institute/reports/advancing-biosimilar-sustainability-in-europe
   Google Scholar
• Simon Kucher & Partners. Payers’ price & market access policies supporting a sustainable biosimilar medicines market: final report. [cited 2018 Oct 31]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2016/09/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication2.pdf
   Google Scholar
• Mielnik P. Drug procurement cooperation (LIS) – norwegian tender system to reduce cost of expensive medicines. JHPOR. 2014;1:18–31.
   Google Scholar
• Raffaelli E, Massimino F. Reference biological medicines (‘originators’) and ‘biosimilars’: competition and patient protection. Ital Antitrust Rev. 2017;4(2):128–176.
   Google Scholar
• National Medical Directorate NHS England. Commissioning framework for biological medicines (including biosimilar medicines). 2017. [cited 2018 Oct 31]. Available from: https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf
   Google Scholar
• Unité d’Achat des Médicaments du CHU de Bordeaux. Règlement de la Consultation de l’accord-cadre. Procédure HMG18 Fourniture de Médicaments: ATOSIBAN - TERLIPRESSINE - INFLIXIMAB - ETANERCEPT. 2017. [cited 2018 Jun 29]. Available from: https://www.boamp.fr/avis/detail/17-77850
   Google Scholar
• Mater Misericordiae University Hospital & St. Vincent’s University Hospital. Request for tenders for the supply of INFLIXIMAB for INFUSION. Open Procedure. 2017. [cited 2018 Jun 29]. Available from: https://irl.eu-supply.com/app/rfq/publicpurchase_frameset.asp?PID=77101&B=ETENDERS_SIMPLE&PS=1&PP=ctm/Supplier/PublicTenders
   Google Scholar
• St James’s Hospital. Invitation to tender open procedure (OJEU) for the provision, supply, support and delivery of infliximab or infliximab biosimilar for infliximab-naïve patients. 2017. [cited 2018 Jun 29]. Available from: https://irl.eu-supply.com/app/rfq/publicpurchase_frameset.asp?PID=109736&B=ETENDERS_SIMPLE&PS=1&PP=ctm/Supplier/PublicTenders
   Google Scholar
• Our Lady’s Children’s Hospital. Supply of Infliximab or biosimilar. 2018. [cited 2018 Jun 29]. Available from: https://irl.eu-supply.com/app/rfq/publicpurchase_frameset.asp?PID=126683&B=ETENDERS_SIMPLE&PS=1&PP=ctm/Supplier/PublicTenders
   Google Scholar
• The Adelaide & Meath Hospital Dublin ITNCsH. Supply and services invitation to tender: supply, delivery of infliximab products. 2017. [cited 2018 Jun 29]. Available from: https://irl.eu-supply.com/app/rfq/publicpurchase_frameset.asp?PID=119661&B=ETENDERS_SIMPLE&PS=1&PP=ctm/Supplier/PublicTenders
   Google Scholar
• Scavone C, Rafaniello C, Berrino L, et al. Strengths, weaknesses and future challenges of biosimilars’ development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice. Pharmacol Res. 2017;126:138–142.
   PubMed Web of Science ®Google Scholar
• Gils A. Combining therapeutic drug monitoring with biosimilars, a strategy to improve the efficacy of biologicals for treating inflammatory bowel diseases at an affordable cost. Dig Dis. 2017;35(1–2):61–68.
   Web of Science ®Google Scholar
• Drake JI, de Hart JCT, Monleon C, et al. Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016. J Mark Access Health Policy. 2017;5(1):1360545.
   PubMedGoogle Scholar
• Frazao TDC, Camilo DGG, Cabral ELS, et al. Multicriteria decision analysis (MCDA) in health care: a systematic review of the main characteristics and methodological steps. BMC Med Inform Decis Mak. 2018;18(1):90.
   PubMedGoogle Scholar
• Kolasa K, Zah V, Kowalczyk M. How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):379–391.
   PubMed Web of Science ®Google Scholar
• Oliveira MD, Mataloto I, Kanavos P. Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. Eur J Health Econ. 2019;20(6):891–918.
   PubMed Web of Science ®Google Scholar
• Bocquet F, Paubel P, Fusier I, et al. Biosimilar hematopoietic growth factors in the public hospitals of Paris: trade--offs between economic goals and evidence based medicine. 2012. [cited 2019 Jan 29]. Available from: http://ageps.aphp.fr/wp-content/blogs.dir/68/files/2013/01/Poster-ISPOR-Berlin.pdf
   Google Scholar